Cogrinding as a tool to produce sustained release behavior for theophylline particles containing magnesium stearate

AAPS PharmSciTech

Volumn 10, Issue 4, 2009, Pages 1243-1251

  Nokhodchi, Ali ^a   Okwudarue, Ononuju N ^a   Valizadeh, Hadi ^b   Momin, Mohammad N ^a  

^a MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cogrinding; Dissolution; Grinding time; Magnesium stearate; Ratio of drug to carrier; Solid state characterization

Indexed keywords

MAGNESIUM STEARATE; THEOPHYLLINE;

ARTICLE; CHEMICAL INTERACTION; CONCENTRATION (PARAMETERS); DISSOLUTION; FOURIER TRANSFORMATION; PH; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; SUSTAINED RELEASE FORMULATION;

CALORIMETRY, DIFFERENTIAL SCANNING; CAPSULES; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; MICROSCOPY, ELECTRON, SCANNING; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STEARIC ACIDS; TECHNOLOGY, PHARMACEUTICAL; THEOPHYLLINE;

EID: 75549087126     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9326-y     Document Type: Article

References (24)

1. M Vogt K Kunath JB Dressman 2008 Cogrinding enhances the oral bioavailability of EMD 57033, a poorly water soluble drug in dogs Eur J Pharm Biopharm 68 338 345 10.1016/j.ejpb.2007.06.011 1:CAS:528:DC%2BD1cXlsF2rtw%3D%3D 17646091
2. M Barzegar-Jalali AM Nayebi H Valizadeh J Hanaee A Barzegar-Jalali K Adibkia, et al. 2006 Evaluation of in vitro-in vivo correlation and anticonvulsive effect of carbamazepine after cogrinding with microcrystalline cellulose J Pharm Pharmaceut Sci 9 307 316 1:CAS:528:DC%2BD28Xht1eitrvP
3. Y Nakai S Nakajima K Yamamoto K Terada T Konno 1980 Effects of grinding on the physical and chemical properties of crystalline medicinals with microcrystalline cellulose. IV Chem Pharm Bull 28 652 1:CAS:528: DyaL3cXhvVGrsbw%3D 7389026
4. Y Sawayanagi N Nambu T Nagai 1983 Enhancement of dissolution properties of prednisolone from ground mixtures with chitin or chitosan Chem Pharm Bull 31 2507 2509 1:CAS:528:DyaL3sXlsVKjtr8%3D
5. K Yamamoto M Nakano K Arita Y Takayama Y Nakai 1976 Dissolution behavior and bioavailability of phenytoin from a ground mixture with microcrystalline cellulose J Pharm Sci 65 1484 10.1002/jps.2600651017 1:CAS:528: DyaE28XlvVagtL0%3D 978407
6. M Vogt K Kunath JB Dressman 2008 Dissolution improvment of four poorly water soluble drugs by cogrinding with commonly used excipients Eur J Pharm Biopharm 68 330 337 10.1016/j.ejpb.2007.05.009 1:CAS:528:DC%2BD1cXlsF2rsQ%3D%3D 17574401
7. M Vogt K Kunath JB Dressman 2008 Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations Eur J Pharm Biopharm 68 283 288 10.1016/j.ejpb.2007.05.010 1:CAS:528:DC%2BD1cXlsF2luw%3D%3D 17574403
8. J Shokri J Hanaee M Barzegar-Jalali R Changizi M Rahbar A Nokhodchi 2006 Improvement of the dissolution rate of indomethacin by a cogrinding technique using polyethylene glycols of various molecular weights J Drug Del Sci Tech 16 203 209 1:CAS:528:DC%2BD28Xntlant74%3D
9. A Nokhodchi Y Javadzadeh MR Siahi M Barzegar-Jalali 2005 The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts J Pharm Pharmaceut Sci 8 18 25 1:CAS:528:DC%2BD2MXivVCgsb8%3D
10. A Nokhodchi R Talari H Valizadeh M Barzegar-Jalali 2007 An investigation on the solid dispersions of chordazepoxide Int J Biomed Sci 3 211 217
11. GG Liversidge KC Cundy 1995 Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: absolute oral bioavailability of nanocrystalline danazol in beagle dogs Int J Pharm 125 91 97 10.1016/0378-5173(95)00122-Y 1:CAS:528:DyaK2MXot12jsr0%3D
12. KY Yang R Glemza CI Jarowski 1979 Effects of amorphous silicon dioxides on drug dissolution J Pharm Sci 68 560 565 10.1002/jps.2600680511 1:CAS:528:DyaE1MXksVCnt7w%3D 219197 (Pubitemid 9186374)
13. T Watanabe I Ohno N Wakiyama A Kusai M Senna 2002 Controlled dissolution properties of indomethacin by compounding with silica STP Pharma Sciences 12 363 367 1:CAS:528:DC%2BD3sXmvVSjtw%3D%3D
14. D Bahl J Hudak R Bogner 2008 Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding Pharm Dev Technol 13 255 269 10.1080/10837450802012869 1:CAS:528:DC%2BD1cXmvFWqu7k%3D 18484494 (Pubitemid 351882244)
15. D Bahl RH Bogner 2008 Amorphization alone does not account for the enhancement of solubility of drug co-ground with silicate: the case of indomethacin AAPS Pharm Sci Tech 9 146 153 10.1208/s12249-007-9013-9
16. T Durig R Fassihi 1997 Mechanistic evaluation of binary effects of magnesium stearate and talc as dissolution retardants at 85% drug loading in an experiment J Pharm Sci 86 1092 1098 10.1021/js970052v 1:STN:280: DyaK1c%2Fgt1ynug%3D%3D 9344163 (Pubitemid 27430911)
17. KA Khan 1975 Concept of dissolution efficiency J Pharm Pharmacol 27 48 49 1:CAS:528:DyaE2MXhsVCru7o%3D 235616
18. A Nokhodchi P Khaseh T Ghafourian MR Siahi-Shadbad 1999 The role of various surfactants and fillers in controlling the release rate of theophylline from HPMC matrices STP Pharma Sciences 9 555 560 1:CAS:528: DC%2BD3cXps1Kgsw%3D%3D
19. W Li-Hua ZT Chowhan 1990 Drug-excipient interactions resulting from powder mixing. V. Role of sodium lauryl sulphate Int J Pharm 60 61 78 10.1016/0378-5173(90)90190-F (Pubitemid 20146167)
20. G Pyramides JW Robinson SW Zito 1995 The combined use of DSC and TGA for the thermal analysis of atenolol tablets J Pharm Biomed Anal 13 103 110 10.1016/0731-7085(94)00112-F 1:CAS:528:DyaK2MXjvVyqt78%3D 7766716
21. GG Oliveira HG Ferraz JSR Matos 2005 Thermoanalytical study of glibenclamide and excipients J Therm Anal Calorimetry 79 267 270 10.1007/s10973-005-0047-5 1:CAS:528:DC%2BD2MXkt1Ciu70%3D
22. A Marini V Berbenni S Moioli G Bruni P Cofrancesco C Margheritis, et al. 2003 Drug-excipient compatibility studies by physico-chemical techniques-the case of indomethacin J Therm Anal Calorimetry 73 529 545 10.1023/A:1025426012578 1:CAS:528:DC%2BD3sXnslGisbo%3D
23. RK Verma S Garg 2004 Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations J Pharm Biomed Anal 35 449 458 10.1016/j.jpba.2004.01.012 1:CAS:528:DC%2BD2cXjvVCjt7s%3D 15137971 (Pubitemid 38609366)
24. MSS Cunha-Filho R Martínez-Pacheco M Landín 2007 Compatibility of the antitumoral β-lapachone with different solid dosage forms excipients J Pharm Biomed Anal 45 590 598 10.1016/j.jpba.2007.08.016 1:CAS:528:DC%2BD2sXht1Grs7vN 17890039 (Pubitemid 350007950)